Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Cardio Diagnostics Holdings, Inc. develops AI-driven epigenetic and genetic blood tests for cardiovascular disease risk assessment and early detection. Its flagship products, Epi+Gen CHD and PrecisionCHD, provide personalized insights to clinicians, payors, and health systems. The company aims to shift cardiovascular care from reactive to proactive, leveraging proprietary technology, strategic partnerships, and a broad market opportunity to improve prevention, diagnosis, and management of heart disease.
This description was generated via AI from an annual report. Updated about 1 year ago.